Amazon asks court to scrap EU tech label, arguing it poses no systemic risks
Amazon asked Europe's second-highest court on Thursday to scrap its designation as a platform subject to stricter requirements under landmark EU online content rules, arguing that it poses no systematic risks to its users.
The Digital Services Act, which came into force in 2022, requires Big Tech companies to do more to tackle illegal and harmful content on their platforms.
The U.S. online retail giant took its grievance to the Luxembourg-based General Court after the European Commission classified it as a very large online platform (VLOP) under the DSA.
A VLOP designation requires companies to do more to tackle illegal online content, undertake risk management, conduct external and independent auditing and share data with authorities and researchers.
'Online marketplaces like the Amazon Store do not pose systemic risks. Second, the VLOP rules do not and cannot rationally assist in preventing the dissemination of illegal or counterfeit goods,' Amazon's lawyer Robert Spano told the court.
'The VLOP rules therefore make no sense when applied to online marketplaces,' he said.
Amazon said any risks are limited to individual customers, not the totality of its users and that even if problematic products exist, widespread exposure is minimal and already dealt with by a number of product safety and compliance laws.
'When it comes to marketplaces like the Amazon Store, size does not multiply risk. It is an arbitrary, disproportionate and discriminatory metric,' Spano said.
The court will rule in the coming months.
Meta Platforms, Chinese social media app TikTok and German online retailer Zalando have also challenged the DSA on various grounds.
The case is T-367/23 – Amazon EU v Commission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
22 minutes ago
- India.com
JACKPOT for investors of this Anil Ambani company as it provides 133% returns in..., not Reliance Power, Reliance Infra, the company is...
Anil Ambani (File) In a major boost for investors of Anil Ambani-led Reliance Group, the shareholders of the group's little-known Reliance Home Finance, has have earned a return of 133 percent on their investment in just month. According to data from the Bombay Stock Exchange (BSE), Reliance Home Finance shares, which were trading below Rs 10 a little while ago, have surged by 133.03 percent in a single month, gaining 18.86 percent in the past week, and an impressive 51.08 percent over two weeks. The stock of Reliance Home Finance has significantly outpaced the more prominent firms of Anil Ambani-led Reliance Group, such as Reliance Power and Reliance Infrastructure. As per data, investor have received one-month return of 133.03 per cent, compounded by a three-month surge of 149.68 percent, and six-month appreciation of over 101 percent. Why Reliance Home Finance stock has surged rapidly? According to analysts, speculative interest, short-term momentum, and low base effect, could be among the factors driving the rise of the stocks, even as the company has not publicly announced any significant turnaround in recent months. Currently, the market capitalisation of Reliance Home Finance stands at Rs 372.63 crore. Meanwhile, despite its golden run, the company lacks a Durability Score, making it ineligible due to weak or inconsistent financials, as per Trendlyne data. Analysts have also warned that the company's stock is currently in the 'P/E Sell Zone', which means it traded below its current P/E ratio of 15.3 nearly 80 percent of the time, indicating that most of the immediate upside could already be priced in. Reliance Infra scripts history Meanwhile, Anil Ambani-led Reliance Infrastructure achieved a historic milestone in India's defense sector, by becoming the first private firm to independently carry out a complete upgrade programme of a military aircraft without an original manufacturer (OEM). According to details, Anil Ambani-led Reliance Infra has successfully upgraded 55 Dornier-228 aircraft under a contract signed with state-owned Hindustan Aeronautics Limited (HAL), in which US-based Genesys Aerosystems was also a technical partner. The initial contract was for 37 aircraft, but Reliance Infra secured another order for 18 more Dornier-228 upgrades after successfully completing the first order.
Time of India
39 minutes ago
- Time of India
Kirti Ganorkar: Why the veteran insider is the right dose for Sun Pharma
Mumbai: For nearly thirty years, Kirti Ganorkar quietly stood at Sun Pharma as a rock, much like his astute boss Dilip Shanghvi , the founder of Sun Pharma. Steadfastly Shanghvi steered Sun Pharma from a small India-focused branded generic player to one that is rapidly emerging as a global specialty drugs company. From September 1, Kirti Ganorkar (58), a chemical engineer and a diehard cricket aficionado, will helm India's largest drugmaker as its managing director, while Shanghvi will continue in the role of executive chairman. In a June 13 statement, Sun Pharma said this marks the culmination of a structured and forward-looking succession planning process, underscoring the organisation's commitment to leadership continuity and strategic governance. For Ganorkar's elevation, the timing is crucial given the global scale of Sun Pharma's operations. It includes a growing and challenging business environment in the US, Europe and a range of emerging markets while keeping Sun Pharma at the top of the intensely competitive home market, India. For FY2025, Sun Pharma had sales of ₹52,041 crore, a 9% growth over the previous year, while its net profit stood at ₹11,984 crore, up 19%. Of which, Sun Pharma's global specialty products sales stood at $1.21 billion (₹10,334 crore), up 17.1%, and accounted for 19.7% of FY25 sales. Alone, Sun Pharma's India sales contribute over 32% of its global revenues. When Ganorkar made his move from German Remedies (acquired later by Zydus Lifesciences in 2001), a united entity for a group of German pharma companies and joined Sun Pharma in 1996 as an executive assistant to Shanghvi, the Indian pharma market was very different. Sun Pharma was at a fraction of its present size. The market was poised for a leap in sales of drugs for heart ailments, diabetes, neurology, and cancer, the segments that have been the primary focus for the company. Now, the dynamics have changed with almost every large Indian company showing prowess of deep reach and scientific expertise as they try to outclass others from in-licensing innovative products to launching their own. Industry experts, who follow Sun Pharma closely, say Ganorkar has a tough task ahead, but the established strength of the company comes as a big help. To succeed Dilip Shanghvi, known for his calculated yet bold moves, Ganorkar will need to combine all his experience. He has held diverse roles at Sun Pharma from business development, marketing, M&A, new product introductions, project management, to intellectual property litigation. An avid cricket follower, Ganorkar is the perfect all-rounder that Shanghvi has chosen. In the new innings, he must demonstrate the skills of MS Dhoni as a cool captain while showing the aggression of Virat Kohli. "Can he be good in the test match format and T20. That is the key," says a senior industry veteran, who was pleasantly surprised to see Ganorkar's new position. Economic Times WhatsApp channel )
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
China misused Interpol's red notice, used Jack Ma to pressure exile abroad
In a striking example of transnational repression, the Chinese government allegedly used billionaire Jack Ma to pressure a prominent exiled businessman into returning to China, part of a broader pattern of Beijing misusing Interpol mechanisms to silence political targets abroad. According to an investigation by the International Consortium of Investigative Journalists (ICIJ), the businessman, identified only as "H", was living in France and awaiting an extradition hearing in 2021 when he received a call from Ma. The Alibaba founder told H, he was asked by Chinese officials to persuade him to return and cooperate in a political case. "They said I'm the only one who can persuade you to return," Ma reportedly told H, who was shocked by the call. Chinese authorities had earlier issued an Interpol red notice accusing H of financial crimes. But court documents reveal the real goal was to force him to testify against Sun Lijun, a former vice minister of public security who had fallen out of favour with Beijing. "I think you don't have any other choice," Ma warned. "If you don't come back, they'll destroy you." H, a naturalised Singaporean citizen, had been arrested in France based on the red notice, a mechanism increasingly used by authoritarian regimes like China to pursue dissidents and political targets overseas. The charges cited in the notice were unrelated to the Sun Lijun case, raising concerns about political manipulation of international law enforcement tools. This case is part of ICIJ's "China Targets" investigation, which found that China has repeatedly used Interpol to track and coerce critics, exiles, and businesspeople abroad. Experts say these tactics undermine the credibility of global police cooperation. Despite growing concerns, Interpol has taken little public action to discipline China for its misuse of red notices, the ICIJ reported. The case of H is a stark reminder of how international institutions can be exploited to carry out authoritarian agendas far beyond national borders. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
